Kathiawad Today

Cystic Fibrosis Pipeline Drugs and Companies Insight Report (2022): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

 Breaking News
  • No posts were found

Cystic Fibrosis Pipeline Drugs and Companies Insight Report (2022): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

November 16
21:30 2022
Cystic Fibrosis Pipeline Drugs and Companies Insight Report (2022): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
Cystic Fibrosis pipeline constitutes 75+ key companies continuously working towards developing 80+ Cystic Fibrosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Cystic Fibrosis Overview

Cystic fibrosis (CF) is a recessive genetic disease caused by a mutation in the epithelial chloride channel—cystic fibrosis transmembrane conductance regulator (CFTR). CF is a predominant genetic disorder with a disease severity ranging from mild to life-threatening. The number of CF patients in a population varies depending on ethnicity. More than 30,000 children and adults in the United States have CF (70,000 worldwide) and CF affects people of every racial and ethnic group. In people with CF, mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene cause the CFTR protein to become dysfunctional.

 

Cystic Fibrosis Pipeline Insight, 2022″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Cystic Fibrosis Market. 

 

The Cystic Fibrosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. 

 

Some of the key takeaways from the Cystic Fibrosis Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Cystic Fibrosis treatment therapies with a considerable amount of success over the years. Cystic Fibrosis Key players such as – Spirovant Sciences, Arcturus Therapeutics, Krystal Biotech, Enterprise Therapeutics, Calithera Biosciences, Verona Pharma, Vertex Pharmaceuticals, and others, are developing therapies for the Cystic Fibrosis treatment 
  • Cystic Fibrosis Emerging therapies such as – SP-101, LUNAR CF, KB407, ETD001, CB280, Ensifentrine, VX-121/Tezacaftor/VX561, and others are expected to have a significant impact on the Cystic Fibrosis market in the coming years.    
  • In September 2021,Vertex Pharmaceuticals initiated a Phase III, Randomized, Double-blind, ControlledStudy Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis (CF) Who AreHeterozygous for F508del and a Minimal Function Mutation (F/MF)
  • The VX-121 + tezacaftor + VX-561 program was granted Fast Track and Orphan Drug designations by the US Food and Drug Administration (FDA), which will facilitate clinical development and expedite regulatory approval.

 

Cystic Fibrosis Pipeline Therapeutics Assessment

  • Cystic Fibrosis Assessment by Product Type
  • Cystic Fibrosis By Stage and Product Type
  • Cystic Fibrosis Assessment by Route of Administration
  • Cystic Fibrosis By Stage and Route of Administration
  • Cystic Fibrosis Assessment by Molecule Type
  • Cystic Fibrosis by Stage and Molecule Type 

 

DelveInsight’s Cystic Fibrosis Report covers around 80+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration 

 

Emerging Cystic Fibrosis Drugs Under Different Phases of Clinical Development Include:

  • SP-101: Spirovant Sciences
  • LUNAR CF: Arcturus Therapeutics
  • KB407: Krystal Biotech
  • ETD001: Enterprise Therapeutics
  • CB280: Calithera Biosciences
  • Ensifentrine: Verona Pharma
  • VX-121/Tezacaftor/VX561: Vertex Pharmaceuticals 

 

Get a Free Sample PDF Report to know more about Cystic Fibrosis Pipeline Assessment – http://delveinsight.com/sample-request/cystic-fibrosis-pipeline?

 

Cystic Fibrosis Pipeline Analysis:

The Cystic Fibrosis pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the Cystic Fibrosis treatment with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cystic Fibrosis Treatment.
  • Cystic Fibrosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Cystic Fibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cystic Fibrosis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Further Cystic Fibrosis product details are provided in the report. Download the Cystic Fibrosis pipeline report to learn more about the emerging Cystic Fibrosis therapies

 

Cystic Fibrosis Pipeline Market Drivers

  • Rising incidence of Cystic Fibrosis
  • Advance research and development over the last few years have contributed to get a clearer picture of the disease
  • Development of the healthcare industry

 

Cystic Fibrosis Pipeline Market Barriers

  • No standard cure for cystic fibrosis
  • Adverse effects associated with the drugs

 

Scope of Cystic Fibrosis Pipeline Drug Insight    

  • Coverage: Global
  • Key Cystic Fibrosis Companies: Spirovant Sciences, Arcturus Therapeutics, Krystal Biotech, Enterprise Therapeutics, Calithera Biosciences, Verona Pharma, Vertex Pharmaceuticals, and others
  • Key Cystic Fibrosis Therapies: SP-101, LUNAR CF, KB407, ETD001, CB280, Ensifentrine, VX-121/Tezacaftor/VX561, and others
  • Cystic Fibrosis Therapeutic Assessment: Cystic Fibrosis current marketed and Cystic Fibrosis emerging therapies
  • Cystic Fibrosis Market Dynamics: Cystic Fibrosis market drivers and Cystic Fibrosis market barriers 

 

Request for Sample PDF Report for Cystic Fibrosis Pipeline Assessment and clinical trials 

 

Table of Contents

1

Cystic Fibrosis Report Introduction

2

Cystic Fibrosis Executive Summary

3

Cystic Fibrosis Overview

4

Cystic Fibrosis- Analytical Perspective In-depth Commercial Assessment

5

Cystic Fibrosis Pipeline Therapeutics

6

Cystic Fibrosis Late Stage Products (Phase II/III)

7

Cystic Fibrosis Mid Stage Products (Phase II)

8

Cystic Fibrosis Early Stage Products (Phase I)

9

Cystic Fibrosis Preclinical Stage Products

10

Cystic Fibrosis Therapeutics Assessment

11

Cystic Fibrosis Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Cystic Fibrosis Key Companies

14

Cystic Fibrosis Key Products

15

Cystic Fibrosis Unmet Needs

16 

Cystic Fibrosis Market Drivers and Barriers

17

Cystic Fibrosis Future Perspectives and Conclusion

18

Cystic Fibrosis Analyst Views

19

Appendix

20

About DelveInsight

Download Sample PDF Report to know more about Cystic Fibrosis drugs and therapies  

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/